Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults — United States, August–December 2021
Supporting Files
Public Domain
-
1 28 2022
-
File Language:
English
Details
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Personal Author:Tenforde, Mark W. ; Patel, Manish M. ; Gaglani, Manjusha ; Ginde, Adit A. ; Douin, David J. ; Talbot, H. Keipp ; Casey, Jonathan D. ; Mohr, Nicholas M. ; Zepeski, Anne ; McNeal, Tresa ; Ghamande, Shekhar ; Gibbs, Kevin W. ; Files, D. Clark ; Hager, David N. ; Shehu, Arber ; Prekker, Matthew E. ; Erickson, Heidi L. ; Gong, Michelle N. ; Mohamed, Amira ; Johnson, Nicholas J. ; Srinivasan, Vasisht ; Steingrub, Jay S. ; Peltan, Ithan D. ; Brown, Samuel M. ; Martin, Emily T. ; Monto, Arnold S. ; Khan, Akram ; Hough, Catherine L. ; Busse, Laurence W. ; Duggal, Abhijit ; Wilson, Jennifer G. ; Qadir, Nida ; Chang, Steven Y. ; Mallow, Christopher ; Rivas, Carolina ; Babcock, Hilary M. ; Kwon, Jennie H. ; Exline, Matthew C. ; Botros, Mena ; Lauring, Adam S. ; Shapiro, Nathan I. ; Halasa, Natasha ; Chappell, James D. ; Grijalva, Carlos G. ; Rice, Todd W. ; Jones, Ian D. ; Stubblefield, William B. ; Baughman, Adrienne ; Womack, Kelsey N. ; Rhoads, Jillian P. ; Lindsell, Christopher J. ; Hart, Kimberly W. ; Zhu, Yuwei ; Naioti, Eric A. ; Adams, Katherine ; Lewis, Nathaniel M. ; Surie, Diya ; McMorrow, Meredith L. ; Self, Wesley H. ; Calhoun, Nicole ; Murthy, Kempapura ; Herrick, Judy ; McKillop, Amanda ; Hoffman, Eric ; Zayed, Martha ; Smith, Michael ; Kindle, Ryan ; Kozikowski, Lori-Ann ; De Souza, Lesley ; Ouellette, Scott ; Thornton-Thompson, Sherell ; Mehkri, Omar ; Ashok, Kiran ; Gole, Susan ; King, Alexander ; Poynter, Bryan ; ten Lohuis, Caitlin ; Stanley, Nicholas ; Hendrickson, Audrey ; Caspers, Sean ; Tordsen, Walker ; Kaus, Olivia ; Scharber, Tyler ; Jorgensen, Jeffrey ; Bowers, Robert ; King, Jennifer ; Aston, Valerie ; Rothman, Richard E. ; Ali, Harith ; Nair, Rahul ; Karow, Sarah ; Robart, Emily ; Maldonado, Paulo Nunes ; Khan, Maryiam ; So, Preston ; Krol, Olivia ; Martinez, Jesus ; Zouyed, Zachary ; Acosta, Michael ; Bazyarboroujeni, Reihaneh ; Jung, Haeun ; Reddy, Raju ; Zhang, Richard ; Gordon, Alexandra Jun ; Levitt, Joe ; Perez, Cynthia ; Visweswaran, Anita ; Roque, Jonasel ; Chandrasekaran, Sukantha ; Angeles, Los ; Frankel, Trevor ; Garner, Omai ; Goff, Jennifer ; Huynh, David ; Jensen, Kelly ; Driver, Conner ; Carricato, Michael ; Chambers, Ian ; Nassar, Paul ; Stout, Lori ; Sibenaller, Zita ; Walter, Alicia ; Mares, Jasmine ; Pfannenstiel, Spenser ; Gershengorn, Hayley ; McSpadden, EJ ; Truscon, Rachel ; Thomas, Lara ; Bielak, Ramsay ; Valvano, Weronika Damek ; Fong, Rebecca ; Fitzsimmons, William J. ; Blair, Christopher ; Gilbert, Julie ; Crider, Christine D. ; Steinbock, Kyle A. ; Paulson, Thomas C. ; Anderson, Layla A. ; Kampe, Christy ; Johnson, Jakea ; Short, Laura L. ; Ezzell, Lauren J. ; Whitsett, Margaret E. ; McHenry, Rendie E. ; Hargrave, Samarian J. ; Blair, Marica ; Luther, Jennifer L. ; Pulido, Claudia Guevara ; Peterson, Bryan P. M. ; LaRose, Mary ; Landreth, Leigha ; Hicks, Madeline ; Parks, Lisa ; Bongu, Jahnavi ; McDonald, David ; Cass, Candice ; Seiler, Sondra ; Park, David ; Hink, Tiffany ; Wallace, Meghan ; Burnham, Carey-Ann ; Arter, Olivia G.
-
Corporate Authors:
-
Description:COVID-19 mRNA vaccines (BNT162b2 [Pfizer-BioNTech] and mRNA-1273 [Moderna]) provide protection against infection with SARS-CoV-2, the virus that causes COVID-19, and are highly effective against COVID-19-associated hospitalization among eligible persons who receive 2 doses (1,2). However, vaccine effectiveness (VE) among persons with immunocompromising conditions* is lower than that among immunocompetent persons (2), and VE declines after several months among all persons (3). On August 12, 2021, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for a third mRNA vaccine dose as part of a primary series ≥28 days after dose 2 for persons aged ≥12 years with immunocompromising conditions, and, on November 19, 2021, as a booster dose for all adults aged ≥18 years at least 6 months after dose 2, changed to ≥5 months after dose 2 on January 3, 2022 (4,5,6). Among 2,952 adults (including 1,385 COVID-19 case-patients and 1,567 COVID-19-negative controls) hospitalized at 21 U.S. hospitals during August 19-December 15, 2021, effectiveness of mRNA vaccines against COVID-19-associated hospitalization was compared between adults eligible for but who had not received a third vaccine dose (1,251) and vaccine-eligible adults who received a third dose ≥7 days before illness onset (312). Among 1,875 adults without immunocompromising conditions (including 1,065 [57%] unvaccinated, 679 [36%] 2-dose recipients, and 131 [7%] 3-dose [booster] recipients), VE against COVID-19 hospitalization was higher among those who received a booster dose (97%; 95% CI = 95%-99%) compared with that among 2-dose recipients (82%; 95% CI = 77%-86%) (p <0.001). Among 1,077 adults with immunocompromising conditions (including 324 [30%] unvaccinated, 572 [53%] 2-dose recipients, and 181 [17%] 3-dose recipients), VE was higher among those who received a third dose to complete a primary series (88%; 95% CI = 81%-93%) compared with 2-dose recipients (69%; 95% CI = 57%-78%) (p <0.001). Administration of a third COVID-19 mRNA vaccine dose as part of a primary series among immunocompromised adults, or as a booster dose among immunocompetent adults, provides improved protection against COVID-19-associated hospitalization.
-
Subjects:
-
Source:MMWR Morbidity Mortal Weekly Rep. 71(4):118-124
-
Series:
-
DOI:
-
ISSN:0149-2195 (print) ; 1545-861X (digital)
-
Pubmed ID:35085218
-
Pubmed Central ID:PMC9351530
-
Document Type:
-
Place as Subject:
-
Pages in Document:7 pdf pages
-
Volume:71
-
Issue:4
-
Collection(s):
-
Main Document Checksum:urn:sha-512:dde19d08c773a8e71b488e2d265accf4a49cc9581c8de98d2c289c2488ce0e67449a0a0d88abfed59a5e1431d010f88f61b2279a870722fb2e1b676a6659cc1e
-
Download URL:
-
File Type:
Supporting Files
File Language:
English
ON THIS PAGE
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings,
journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
Morbidity and Mortality Weekly Report (MMWR)